Differential effects on in vitro bone resorption were observed when the glucocorticoids, hydrocortisone and dexamethasone, were added to neonatal mouse calvariae treated with either parathyroid hormone (PTH), 1,25(OH) 2 -vitamin D 3 , all trans-retinoic acid (t-RA), or prostaglandin E 2 (PGE 2 
Introduction
The description of hypercortisolemia by Cushing in 1932 suggested an increased tendency for skeletal fractures in patients (Cushing 1932) . Increased concentrations of glucocorticoids are thought to alter bone remodeling by decreasing bone formation and increasing bone resorption (Adler & Rosen 1994 , Lukert & Raisz 1994 , Reid et al. 1994 . The increase in bone resorption occurring with glucocorticoid excess is considered to be due, in large measure, to the development of secondary hyperparathyroidism (Fucik et al. 1975) .
In vitro studies which have addressed the possibility of a direct role of glucocorticoids in bone resorption have yielded non-uniform results. Early investigations employing fetal rat limb bones in culture (Stern 1969 and studies using isolated osteoclasts (Tobias & Chambers 1989) have suggested that glucocorticoids decrease osteoclast function and inhibit bone resorption. On the other hand, in co-cultures of mouse bone marrowderived stromal cells and spleen cells (Udagawa et al. 1989) , and in mouse bone marrow cultures (Shuto et al. 1994 , M Ransjö, A Lie & U H Lerner, unpublished data), dexamethasone has been shown to enhance osteoclast-like cell differentiation induced by 1,25(OH) 2 -vitamin D 3 and to increase the capacity of the cells to promote pit formation on dentine slices. Additionally, stimulation of bone resorption has been observed in organ culture studies following glucocorticoid treatment of both fetal rat parietal bones (Gronowicz et al. 1990 ) and neonatal mouse calvariae (Reid et al. 1986 , Lowe et al. 1992 , Conaway et al. 1996 .
In a recent investigation, we have observed stimulation of neonatal mouse calvarial bone resorption with the glucocorticoids, hydrocortisone and dexamethasone (Conaway et al. 1996) . Furthermore, we have found that this resorption could be blunted by two modulators of glucocorticoid receptor binding, progesterone and RU 38486 (a derivative of 19-nortestosterone), and by three inhibitors of osteoclastic bone resorption, calcitonin, acetazolamide and the bisphosphonate AHPrBP. Additionally, there are numerous effects of the glucocorticoids which suggest that the actions of other osteolytic agents might be altered in the presence of these compounds. These include reports of the glucocorticoids increasing cellular receptor numbers for important calcium regulatory hormones such as PTH (Yamamoto et al. 1988 ) and 1,25(OH) 2 -vitamin D 3 (Chen et al. 1983) , interactions between glucocorticoids and retinoids on the patterns of gene transcription and expression of proteins in a variety of different cells (reviewed in Gudas et al. 1994) , and alterations of cell surface oligosaccharides by glucocorticoids, which increase the binding of cells to bone (Bar-Shavit et al. 1984) . Because of such observations, the present study was initiated to determine if resorption in neonatal mouse calvarial bones induced by different peptide and steroidlike hormones might be modulated by glucocorticoids.
Materials and Methods
Synthetic bovine PTH 1-34 was purchased from Bachem, Bubendorf, Switzerland; CMRL 1066 medium ormodification of Minimum Essential Medium ( -MEM) from Gibco, Renfrewshire, Scotland; 45 Ca[CaCl 2 ] from DuPont/New England Nuclear, Dreieich, Germany; -[5-
3 H]proline from The Radiochemical Centre, Amersham, Bucks, UK; multiwell plastic culture dishes from Costar, Cambridge, MA, USA; bovine serum albumin (RIA grade), hydrocortisone, dexamethasone, progesterone, trans-retinoic acid (t-RA), and prostaglandin E 2 (PGE 2 ) from Sigma Chemical Company, St Louis, MO, USA. Indomethacin was a gift from Merch, Sharp and Dohme, Haarlem, The Netherlands; RU 38486 (mifepristone; 17 -hydroxy-11 -(4-dimethyl aminophenyl)17 -(1-propynyl)-estra-4, 9 dien-3-one) from Roussel-UCLAF, Romanville, France and 1( ),25(OH) 2 -vitamin D 3 from Hoffmann-LaRoche, Basle, Switzerland. Indomethacin, hydrocortisone, dexamethasone, progesterone, RU 38486, t-RA, 1,25(OH) 2 -vitamin D 3 , and PGE 2 were dissolved in 99% ethanol before dilution in medium to the stated concentrations. PTH was dissolved at a concentration of 10 µmol/l in 1 mmol/l HCl containing 1 g/l albumin. The final concentration of different vehicles never exceeded 0·1%.
Tissue culture technique
Parietal bone explants from 6-to 7-day-old CsA mice were used for study. The parietal bones were divided along the sagittal suture producing two calvarial halves. The posterior two-thirds of each calvarial half was divided into anterior and posterior portions producing four bone fragments (Ljunggren et al. 1991) . Microdissected parietal bone fragments (four/one calvarium) were employed in all experiments. The parietal bones were preincubated for 18 to 24 h in either CMRL 1066 or -MEM medium containing 0·1% albumin and 1 µmol/l indomethacin (Lerner 1987) . Following preincubation, the bones were washed extensively in Tyrode's solution and subsequently cultured for 120 h in multiwell culture dishes (one bone/ well) containing 2·0 ml medium with 0·1% albumin with or without added test solutions. During both preculture and experimental intervals, the parietal bones were incubated with 5% CO 2 in humidified air at 37 C.
Analysis of mineral mobilization
At the end of the experiments, bones from mice injected with 1·5 µCi [
45 Ca]CaCl 2 four days prior to dissection were dissolved in HCl and aliquots of media and bones analyzed for radioactivity by liquid scintillation. The extent of bone resorption was evaluated by the release of 45 Ca from bones to the culture medium, expressed as a percentage of initial radioactivity present in bones (Lerner 1987) .
Determination of matrix degradation
Mice were subcutaneously injected with 10 µCi [ 3 H]proline four days before calvarial bone dissection. At the end of experimentation, aliquots of media and hydrolyzed bone samples were analyzed for 3 H and the percentage release of 3 H to the culture medium determined as described previously (Lerner 1987 (Brand & Raisz 1972) , thus 3 H release is considered to be a good indicator of collagen breakdown.
Statistical analysis
Statistical calculations were made with Student's t-test for unpaired samples.
Results
Experiments were performed initially to evaluate the effects of glucocorticoids in the absence and presence of PTH. These results are shown in Fig. 1 . The release of 45 Ca (Fig. 1a) was significantly greater than control (P<0·01) for 10 6 mol/l hydrocortisone, 10 6 mol/l dexamethasone, 3 10 11 mol/l PTH, 10 6 mol/l hydrocortisone plus 3 10 11 mol/l PTH, and 10 6 mol/l dexamethasone plus 3 10 11 mol/l PTH following 120 h of culture. After subtraction of control resorption, the mean values of 45 Ca release observed with the hydrocortisone plus PTH treatment combination (30·8%) and the dexamethasone plus PTH treatment combination (26·4%) were greater than the expected 45 Ca release which would have been stimulated by hydrocortisone and PTH (14·9%) and by dexamethasone and PTH (17·3%) if additive effects had occurred. Similar results were found when collagen breakdown, as assessed by 3 H release, was determined following exposure of calvarial bones to glucocorticoids and PTH (Fig. 1b ). Significant release (P<0·01) of 3 H to culture media was noted following treatment with 3 10 11 mol/l PTH, 10 6 mol/l hydrocortisone plus 3 10 11 mol/l PTH, and 10 6 mol/l dexamethasone plus 3 10 11 mol/l PTH for 120 h. Furthermore, the mean values of 3 H release minus control observed with the hydrocortisone plus PTH combination (43·2%) and the dexamethasone plus PTH combination (47·6%) were greater than the expected 3 H release for hydrocortisone and PTH (21·7%) and for dexamethasone and PTH (24·6%) if additive effects had been obtained.
To evaluate the interaction between glucocorticoids and PTH further, 45 Ca release from neonatal mouse calvariae was determined at different treatment levels of PTH in the presence of uniform dosages of hydrocortisone and dexamethasone. These experiments are plotted as a percentage of the control, which was set at 100%. Figure 2a indicates the data obtained following addition of 10 6 mol/l hydrocortisone for 120 h to PTH concentrations ranging from 3 10 12 to 10 8 mol/l. Significant release (P<0·01) of 45 Ca was observed with 10 6 mol/l hydrocortisone and when PTH was added to cultures at dosage levels of 3 10 11 to 10 8 mol/l. At 10 11 to 10 9 mol/l PTH, the release of 45 Ca in the presence of 10 6 mol/l hydrocortisone was greater than the expected release of 45 Ca which would have been 6 mol/l hydrocortisone (a) and 10 6 mol/l dexamethasone (b) to mouse calvarial bones exposed to incremental concentrations of PTH. Calvariae were cultured for 120 h as described in Materials and Methods. Results presented in (a) are from two independent experiments and those in (b) from five experiments. The data have been pooled by recalculating the values obtained for treated bones in each experiment relative to untreated control values which were set to 100%. Values shown are means for 10-25 bones and S.E.M. is shown as vertical bars. The untreated control bones in the seven experiments released 21·1 0·7, 19·9 0·9, 18·4 0·6, 26·7 2·9, 20·1 2·3, 29·1 2·5, and 33·3 1·6% 45 Ca (means S.E.M.; n=5). The effects of PTH alone were significantly different (P<0·01) at and above 3 10 11 mol/l in both (a) and (b). The effects of hydrocortisone and dexamethasone alone were significantly different (P<0·01) from untreated controls.
stimulated by hydrocortisone and PTH in an additive fashion. Greater than additive 45 Ca release from neonatal mouse calvariae was also observed when dexamethasone was added to varying concentrations of PTH. Figure 2b shows the effects of 10 6 mol/l dexamethasone addition to PTH dosage levels of 10 11 to 10 8 mol/l. The release of 45 Ca to culture medium was increased significantly (P<0·01) by 10 6 mol/l dexamethasone and by addition of PTH at concentrations of 3 10 11 to 10 8 mol/l. In agreement with the previous experiments, the release of 45 Ca at 10 11 to 10 9 mol/l PTH in the presence of 10 6 mol/l dexamethasone was greater than the 45 Ca release stimulated by dexamethasone and PTH alone. On the other hand, at supraoptimal concentrations of PTH (>10 9 mol/l), 45 Ca release which occurred in the presence of either hydrocortisone or dexamethasone was not greater than additive (Fig. 2a,b) .
In the next series of experiments, 3 10 11 mol/l PTH was evaluated with varying concentrations of the glucocorticoids. Figure 3a shows the results of 3 10 11 mol/l PTH addition to calvarial bones exposed to 10 8 to 10 6 mol/l hydrocortisone for 120 h. The release of 45 Ca from calvariae was increased significantly (P<0·01) by 3 10 11 mol/l PTH and by hydrocortisone concentrations of 3 10 8 to 10 6 mol/l. At 3 10 8 to 10 6 mol/l hydrocortisone, the increased 45 Ca release observed in the presence of PTH was again synergistic. Similar results were obtained when 3 10 11 mol/l PTH was added to 10 9 to 3 10 7 mol/l dexamethasone (Fig. 3b) Ca to culture medium was observed at 48, 72, 96 and 120 h when calvariae were exposed to 10 6 mol/l hydrocortisone, and at 24 to 120 h when exposed to 3 10 11 mol/l PTH. Synergistic stimulation of 45 Ca release by the hydrocortisone plus PTH combination was apparent after 72 h of culture. At this time point, the percentage 45 Ca release from calvariae treated with both hydrocortisone and PTH was 20·1% after subtraction of control values, in comparison to an expected 12·6% if additive stimulation had occurred. Similar data were obtained in time course studies when 3 10 11 mol/l PTH was combined with 10 6 mol/l dexamethasone (data not shown).
In agreement with a previous study (Conaway et al. 1996) , progesterone (10 5 mol/l) and RU 38486 (10 6 mol/l) abolished the stimulatory effect of hydrocortisone (10 6 mol/l) on 45 Ca release, without affecting the basal release of radioactive calcium (Fig. 5) . In addition, synergistic stimulation of 45 Ca release resulting from co-treatment with 10 6 mol/l dexamethasone and suboptimal concentrations of PTH (3 10 11 and 7 10 11 mol/l) was blocked by both progesterone (10 5 mol/l) and RU 38486 (10 6 mol/l). After observing synergistic stimulation of neonatal mouse calvarial bone resorption with the glucocorticoids and PTH, additional agents were tested with hydrocortisone and dexamethasone. Figure 6 shows the data Ca from neonatal mouse calvariae was also found after 120 h of culture in the presence of 10 8 mol/l t-RA and following treatment with 3 10 8 mol/l dexamethasone (Fig. 7) . However, not only was enhancement of mineral mobilisation not observed, but calvarial 45 Ca release was decreased to control levels when t-RA and dexamethasone were combined.
Lastly, experiments were performed to test for interactions between the glucocorticoids and PGE 2 . In this study, significant release (P<0·05) of 45 Ca from neonatal mouse calvariae was found at 120 h with hydrocortisone and dexamethasone, and when the bone explants were exposed to 3 10 8 and 3 10 7 mol/l PGE 2 (Fig. 8) . However, the 45 Ca release observed after combining the glucocorticoids with PGE 2 was not greater than additive, although in the same experiments synergistic stimulation of mineral mobilization was recorded when either 10 6 mol/l hydrocortisone or 10 6 mol/l dexamethasone was combined with 7 10 11 mol/l PTH.
Discussion
The present investigation confirms earlier studies (Reid et al. 1986 , Lowe et al. 1992 , Conaway et al. 1996 which showed a direct stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids, hydrocortisone and dexamethasone. Furthermore, assessment of both mineral and matrix release indicated that increased bone resorption occurred when either hydrocortisone or dexamethasone was added to neonatal mouse calvariae treated with PTH. Reid et al. (1986) have also reported an increase in neonatal mouse calvarial bone resorption following treatment with hydrocortisone and PTH. However, the increase found by Reid et al. (1986) was additive, rather than synergistic. In the current study, tests of different dosage levels of the glucocorticoids and PTH showed that the stimulation of neonatal mouse calvarial bone resorption by combination treatment was greater than the sum of the additive effects of the agents tested separately, indicating that the interaction between the glucocorticoids and PTH for stimulation of calvarial bone resorption was synergistic.
Two agents which can modulate glucocorticoid action, progesterone and RU 38486, have been shown previously to inhibit the stimulation of neonatal mouse calvarial bone resorption by hydrocortisone and dexamethasone without affecting either control or PTH-stimulated resorption (Conaway et al. 1996) . These observations were confirmed in the present study and, in addition, it was found that the synergistic stimulation of bone resorption resulting from co-treatment with the glucocorticoids and PTH was inhibited by progesterone and RU 38486. Moreover, time course studies of the combined treatment with the glucocorticoids and PTH indicated that the synergistic enhancement of bone resorption was not an immediate effect, but required several days of culture to develop. These results suggest that nuclear events are involved in the interaction between the glucocorticoids and PTH, a view compatible with the generally proposed genomic action of glucocorticoids mediated via steroid hormone receptors.
Synergistic potentiation of bone resorption was also observed when glucocorticoids were added to mouse calvariae treated with 1,25(OH) 2 -vitamin D 3 . Although an involvement of 1,25(OH) 2 -vitamin D 3 in glucocorticoidinduced osteoporosis has not been established as firmly as the role of PTH, serum levels of not only PTH, but also 1,25(OH) 2 -vitamin D 3 have been reported to be increased in asthmatic patients receiving glucocorticoids (Bikle et al. 1993) .
The stimulation of osteoclastic bone resorption by PTH and 1,25(OH) 2 -vitamin D 3 is believed to be indirect, and mediated by osteoblasts (reviewed in Vaes 1988) . Glucocorticoids have been shown to have effects on osteoblasts which might play a role in the synergistic enhancement of neonatal mouse calvarial bone resorption which occurs in the presence of PTH and 1,25(OH) 2 -vitamin D 3 . In the case of PTH, studies suggest that glucocorticoids may increase the sensitivity of osteoblasts to the peptide. There is greater inhibition by PTH of collagen synthesis, alkaline phosphatase activity, and citrate decarboxylation in osteoblasts when glucocorticoids are present (Wong 1979 , mol/l dexamethasone (DEX) to neonatal mouse calvariae exposed to 10 8 mol/l t-RA. Calvarial bones were cultured for 120 h as described in Materials and Methods. Values are based on means for five bones and S.E.M. is represented as vertical bars. The stimulatory effects of dexamethasone and t-RA were statistically different (P<0·01) from untreated controls. The effect of dexamethasone+t-RA was statistically different (P<0·01) from t-RA alone. Heersche et al. 1981) . Glucocorticoid treatment has also been reported to increase PTH receptor availability and PTH-stimulated cyclic AMP formation in isolated osteoblasts and in osteosarcoma cells (Chen & Feldman 1979 , Yamamoto et al. 1988 .
The data showing that glucocorticoids do not synergistically potentiate the bone resorptive effect of PGE 2 tend to rule out an involvement of prostaglandins in the synergistic stimulation of resorption seen in calvarial bones following treatment with glucocorticoids and either PTH or 1,25(OH) 2 -vitamin D 3 . Furthermore, since both PGE 2 and PTH stimulate cyclic AMP production in neonatal mouse calvariae, the data suggest that interaction between the glucocorticoids and PTH is not due to enhancement of cyclic AMP formation.
Additionally, glucocorticoids have been found to increase 1,25(OH) 2 -vitamin D 3 receptors in isolated rat osteoblasts (Chen et al. 1983) . However, this effect may be species specific, for glucocorticoid exposure has also been reported to decrease 1,25(OH) 2 -vitamin D 3 receptors in mouse osteoblasts (Chen et al. 1982) . On the other hand, dexamethasone treatment of mouse bone marrow cultures and co-cultures of mouse bone marrow-derived stromal cells and spleen cells has been shown to increase osteoclast-like cell differentiation and function stimulated by 1,25(OH) 2 -vitamin D 3 (Tobias & Chambers 1989 , Udagawa et al. 1989 , observations that we have confirmed using bone marrow cultures from the same mouse strain that was used for the calvarial studies (Ransjö, Lie & Lerner, unpublished data) . In mouse bone marrow cultures, several cytokines, with both inhibitory and stimulatory effects, have also been shown to affect the proliferation, differentiation, and fusion of mononuclear osteoclast progenitor cells into multinucleated osteoclasts (reviewed in Suda et al. 1992) . Recently, evidence has been presented that glucocorticoids potentiate the effect of 1,25(OH) 2 -vitamin D 3 on osteoclast formation in bone marrow cultures by decreasing the expression of granulocyte-macrophage colony stimulating factor (GM-CSF; Shuto et al. 1994) . In a previous study, it was shown that GM-CSF is not inhibitory in the calvarial assay (Conaway et al. 1996) , which suggests that it is unlikely that this mechanism is involved in the interaction between glucocorticoids and 1,25(OH) 2 -vitamin D 3 in mouse calvariae. In another recent investigation using bone marrow cells, Udagawa et al. (1994) have reported that dexamethasone increases the expression of the soluble interleukin-6 (IL-6) receptor, and these authors have suggested that this may be an important mechanism for glucocorticoid interactions. However, we have not been able to show an effect of recombinant mouse IL-6 (10-10 000 U/ml) on 45 Ca release in neonatal mouse calvariae in either the absence or the presence of dexamethasone (H H Conaway and U H Lerner, unpublished data). Thus, it seems unlikely that either IL-6 or the glucocorticoid-inducable IL-6 receptor might be major determinants in the interactions noted between the glucocorticoids and other peptide and steroid-like hormones in the current investigation.
Vitamin A (retinol) is an additional agent believed to play an important regulatory role in calcium metabolism (Raisz & Kream 1981) . In contrast to the synergistic effects noted when glucocorticoids were combined with either PTH or 1,25(OH) 2 -vitamin D 3 , co-treatment of calvarial bones with t-RA and dexamethasone reduced 45 Ca release to control values. There have been numerous studies which have shown opposing effects of glucocorticoids and retinoids (Roberts et al. 1984 , Goldman 1985 , Oberg & Carpenter 1989 , Violette et al. 1989 . The results obtained with glucocorticoids and retinoids in the current investigation are aligned most closely with a previous study on transcriptional control in UMR 201 preosteoblasts. In UMR 201 preosteoblasts, it was found that transcriptional activity of an osteonectin-chloramphenicol acetyltransferase construct was increased by treatment with either dexamethasone or retinoic acid alone, but that transcriptional activity was attenuated in the presence of both compounds (Ng et al. 1989) .
In some instances, opposing effects of the glucocorticoids and retinoids may involve changes in receptor expression and function. In rat hepatocytes, dexamethasone has been reported to both decrease retinoic acid receptors (Pallet et al. 1996) and increase the expression of retinoid X receptor (RXR) genes (Wan et al. 1994) , Figure 8 Differential stimulation of 45 Ca release following addition of 10 6 mol/l hydrocortisone and 10 6 mol/l dexamethasone to calvariae treated with PGE 2 (3 10 8 , 3 10 7 mol/l) and PTH (7 10 11 mol/l). Bones were cultured for 120 h as described in Materials and Methods. Values are based on means for five bones and S.E.M. is represented as vertical bars. The effects of PTH or PGE 2 alone and in combination with either hydrocortisone or dexamethasone were statistically significant (P<0·05) compared with untreated controls.
while retinoids have been found to alter the binding capacity of the glucocorticoid receptor and its translocation from the cytosol to the nucleus (Audouin-Chevallier et al. 1995) . Modulation of receptors might provide the basis for repression of resorption in the presence of both glucocorticoids and retinoids.
In summary, the effects of glucocorticoids on calcium metabolism are complex. Glucocorticoid therapy is suggested to alter calcium balance, causing increased secretion of PTH. While PTH secretion is believed to play a central role in the bone resorption associated with glucocorticoidinduced osteoporosis, increased secretion of PTH may not provide a complete explanation of the disorder. Although it is unclear how well the current in vitro data may prove to parallel the in vivo situation, the present investigation provides evidence of still other possible roles for the glucocorticoids, that of synergistically interacting with important resorptive hormones such as PTH and 1,25(OH) 2 -vitamin D 3 to potentiate osteoclastic bone resorption caused by these agents, as well as acting in an opposing fashion with another important bone active agent, t-RA.
